201 related articles for article (PubMed ID: 12820306)
1. Trypsinogen activation peptide (TAP) expression in gallbladder bile identifies bilio-pancreatic carcinoma.
Brockmann JG; Hernandez CA; Emparan C; Wolters H; Haier J; Dietl KH; Senninger NJ
Anticancer Res; 2003; 23(2A):819-25. PubMed ID: 12820306
[TBL] [Abstract][Full Text] [Related]
2. Gallbladder bile tumor marker quantification for detection of pancreato-biliary malignancies.
Brockmann J; Emparan C; Hernandez CA; Sulkowski U; Dietl KH; Menzel J; Wolters H; Glodny B; Senninger N
Anticancer Res; 2000; 20(6D):4941-7. PubMed ID: 11326643
[TBL] [Abstract][Full Text] [Related]
3. The value of biliary amylase and Hepatocarcinoma-Intestine-Pancreas/Pancreatitis-associated Protein I (HIP/PAP-I) in diagnosing biliary malignancies.
Chen CY; Lin XZ; Wu HC; Shiesh SC
Clin Biochem; 2005 Jun; 38(6):520-5. PubMed ID: 15885230
[TBL] [Abstract][Full Text] [Related]
4. A new strategy for the application of CA19-9 in the differentiation of pancreaticobiliary cancer: analysis using a receiver operating characteristic curve.
Kim HJ; Kim MH; Myung SJ; Lim BC; Park ET; Yoo KS; Seo DW; Lee SK; Min YI
Am J Gastroenterol; 1999 Jul; 94(7):1941-6. PubMed ID: 10406263
[TBL] [Abstract][Full Text] [Related]
5. [Role of carcinoembryonic antigen, carbohydrate antigen 19-9 and cytology of bile in diagnosis of biliary and pancreatic cancer].
Matsuda M; Shimizu Y; Chikamatsu E; Takayanagi K; Ishigure H; Murakami S; Odani K
Nihon Geka Gakkai Zasshi; 1991 Jun; 92(6):716-21. PubMed ID: 1886576
[TBL] [Abstract][Full Text] [Related]
6. [Computerized methods in the diagnosis and prognosis of surgically treated bilio-pancreatic diseases].
Festa T; Foco A; Serenthà U; Enrichens F; Sciascia C; Caponi R; Manconi P; Grande L; Vogliolo B; Cardone M; Fornero G; Barberio V; Giordano A; Curti B; Pasquino M
Minerva Med; 1983 Feb; 74(7):289-300. PubMed ID: 6338420
[TBL] [Abstract][Full Text] [Related]
7. Usefulness of bile cytology in the diagnostic management of patients with biliary tract obstruction.
Cobb CJ; Floyd WN
Acta Cytol; 1985; 29(2):93-100. PubMed ID: 2984868
[TBL] [Abstract][Full Text] [Related]
8. Ki-ras mutations in codon 12 and p53 mutations (biomarkers) and cytology in bile in patients with hepatobiliary-pancreatic carcinoma.
Yamaguchi K; Nakano K; Nagai E; Chijiiwa K; Kinoshita M; Ohta M; Tanaka M
Hepatogastroenterology; 2005; 52(63):713-8. PubMed ID: 15966189
[TBL] [Abstract][Full Text] [Related]
9. Fibronectin in human bile fluid for diagnosis of malignant biliary diseases.
Körner T; Kropf J; Hackler R; Brenzel A; Gressner AM
Hepatology; 1996 Mar; 23(3):423-8. PubMed ID: 8617420
[TBL] [Abstract][Full Text] [Related]
10. [Urine diacetylspermine as a novel tumor marker for pancreatobiliary carcinomas].
Yamaguchi K; Nagano M; Torada N; Hamasaki N; Kawakita M; Tanaka M
Rinsho Byori; 2004 Apr; 52(4):336-9. PubMed ID: 15164602
[TBL] [Abstract][Full Text] [Related]
11. Mac-2-binding protein is a diagnostic marker for biliary tract carcinoma.
Koopmann J; Thuluvath PJ; Zahurak ML; Kristiansen TZ; Pandey A; Schulick R; Argani P; Hidalgo M; Iacobelli S; Goggins M; Maitra A
Cancer; 2004 Oct; 101(7):1609-15. PubMed ID: 15378479
[TBL] [Abstract][Full Text] [Related]
12. [Fibronectin in human bile--a new parameter for diagnosis of malignant bile duct processes?--A pilot study].
Körner T; Kropf J; Jaspersen D; Schorr W; Hammar CH; Gressner AM
Z Gastroenterol; 1994 Feb; 32(2):87-90. PubMed ID: 8165831
[TBL] [Abstract][Full Text] [Related]
13. [Peroral endoscopical diagnosis for the early stage of cancer in bilio-pancreatic system].
Murashima Y; Suga T; Koito K; Miyakawa H; Sato T
Rinsho Byori; 1990 Mar; 38(3):231-9. PubMed ID: 2190021
[TBL] [Abstract][Full Text] [Related]
14. The clinical value of serum CEA, CA19-9, and CA242 in the diagnosis and prognosis of pancreatic cancer.
Ni XG; Bai XF; Mao YL; Shao YF; Wu JX; Shan Y; Wang CF; Wang J; Tian YT; Liu Q; Xu DK; Zhao P
Eur J Surg Oncol; 2005 Mar; 31(2):164-9. PubMed ID: 15698733
[TBL] [Abstract][Full Text] [Related]
15. [Tumor markers in the diagnosis of tumors in the subhepatic area].
Dufek V; Petrtýl J; Klener P; Chmel J
Vnitr Lek; 1994 Jun; 40(6):350-3. PubMed ID: 8073643
[TBL] [Abstract][Full Text] [Related]
16. Comparison of tumor marker CA 242 with CA 19-9 and carcinoembryonic antigen (CEA) in pancreatic cancer.
Ozkan H; Kaya M; Cengiz A
Hepatogastroenterology; 2003; 50(53):1669-74. PubMed ID: 14571813
[TBL] [Abstract][Full Text] [Related]
17. [Does cholestasis change the clinical usefulness of CA 19-9 in pacreatobiliary cancer?].
Mery CM; Duarte-Rojo A; Paz-Pineda F; Gómez E; Robles-Díaz G
Rev Invest Clin; 2001; 53(6):511-7. PubMed ID: 11921523
[TBL] [Abstract][Full Text] [Related]
18. Activation of telomerase and its diagnostic application in biopsy specimens from biliary tract neoplasms.
Niiyama H; Mizumoto K; Kusumoto M; Ogawa T; Suehara N; Shimura H; Tanaka M
Cancer; 1999 May; 85(10):2138-43. PubMed ID: 10326691
[TBL] [Abstract][Full Text] [Related]
19. DNA image cytometry in the differential diagnosis of benign and malignant lesions of the bile duct, the pancreatic duct and the papilla of Vater.
Biesterfeld S; Deacu L
Anticancer Res; 2009 May; 29(5):1579-84. PubMed ID: 19443369
[TBL] [Abstract][Full Text] [Related]
20. [The clinical value of tumor marker CA50 and CA242 in digestive tract cancer].
Huang C; Bei L; Liu T
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 1998 Aug; 20(4):285-8. PubMed ID: 11367693
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
